Overview
This research study is trying to determine if Low-Intensity shock wave therapy (LiSWT) is safe and effective in patients with symptoms of erectile dysfunction (ED) after radical prostatectomy.
Description
Participants will be randomized to the active treatment group or the control/placebo group.
All patients on active treatment will receive Low-Intensity shock wave treatment. Participants assigned to the control group will receive the treatment using a sham applicator. The placebo group will receive the same treatment as the active group, but the transducer used for shock wave treatment will be capped, meaning that no shock waves will be transmitted to the penis.
Participants on active shock wave treatment will receive once a week Low-Intensity shock wave treatments of 0.2 mJ/ mm² over the lateral penile shaft (distal, mid, and proximal penile shaft), 500 impulses in each area, for a total of 1500 shocks along the penis once a week for six weeks, with a total of 6 treatments once a week.
Eligibility
Inclusion Criteria:
- Men age 45-70 who had robotic prostatectomy within 6 to 18 months
- Documented nerve sparing during radical prostatectomy procedure
- Mild to moderate ED after prostatectomy
- IIEF score > 18 before surgery
- Testosterone level > 300 mg/dl post-surgery
- Sexually active
Exclusion Criteria:
- Prior penile surgery
- Lesions or active infections on the penis or perineum
- Anatomical abnormalities in the genitalia or pelvic region
- Unwilling to remove piercing from genital region
- Post radical prostatectomy complications that could impact safety or effectiveness of ESWT (hematoma, unresolved anastomotic leak)
- Previous or scheduled treatment with pelvic radiotherapy and/or androgen deprivation therapy
- Anticoagulant medication (except acetylsalicylic acid up to 80 mg daily).
- Any other condition that would prevent the patient from completing the study, as judged by the PI